JAK2-STAT3信号通路在肿瘤发生发展中的作用

doi:10.3760/cma.j.cn371439-20210428-00146

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (12): 739-742.doi: 10.3760/cma.j.cn371439-20210428-00146

JAK2-STAT3信号通路在肿瘤发生发展中的作用

罗盼¹, 曾艳¹, 吴伟莉^1,^2,³()

¹贵州医科大学临床医学院肿瘤学教研室,贵阳 550000
²贵州医科大学附属医院肿瘤科,贵阳 550000
³贵州医科大学附属肿瘤医院头颈肿瘤科,贵阳 550000

收稿日期:2021-04-28 修回日期:2021-06-26 出版日期:2021-12-08 发布日期:2022-01-12
通讯作者: 吴伟莉 E-mail:wwlmhy@163.com
基金资助:
贵州省科技计划(黔科合基础〔2017〕)(1148);贵州省教育厅创新群体重大研究项目(黔教合KY字〔2017〕)(038)

Role of JAK2-STAT3 signaling pathway in tumorigenesis and development

Luo Pan¹, Zeng Yan¹, Wu Weili^1,^2,³()

¹Department of Oncology, School of Clinical Medicine, Guizhou Medical University, Guiyang 550000, China
²Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang 550000, China
³Depart-ment of Head and Neck Oncology, Cancer Hospital Affiliated of Guizhou Medical University, Guiyang 550000, China

Received:2021-04-28 Revised:2021-06-26 Online:2021-12-08 Published:2022-01-12
Contact: Wu Weili E-mail:wwlmhy@163.com

摘要/Abstract

摘要：

JAK2-STAT3信号通路作为细胞内传递信号的主链,在细胞增殖、凋亡、侵袭、迁移及免疫应答等活动中起重要作用。该通路由细胞因子和干扰素触发,能迅速地将细胞外信号转导到细胞核中,在头颈部鳞状细胞癌、肺癌、食管癌、胃癌、肝癌、乳腺癌、骨髓增生性肿瘤等多种肿瘤中存在异常表达。深入了解JAK2-STAT3信号通路的致癌机制,可为临床治疗肿瘤及判断预后提供新的思考。

关键词: 肿瘤, JAK2-STAT3信号通路

Abstract:

JAK2-STAT3 signaling pathway, as the main chain of intracellular signal transmission, plays an important role in cell proliferation, apoptosis, invasion, migration and immune response. Triggered by cytokines and interferon, this pathway can quickly transduce extracellular signals into the nucleus, and it has abnormal expression in various tumors, such as squamous cell carcinoma of the head and neck, lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer and myeloproliferative neoplasms. Further understanding of the carcinogenic mechanism of JAK2-STAT3 signaling pathway can provide new ideas for clinical treatment of tumors and prognosis.

Key words: Neoplasms, JAK2-STAT3 signaling pathway

罗盼, 曾艳, 吴伟莉. JAK2-STAT3信号通路在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2021, 48(12): 739-742.

Luo Pan, Zeng Yan, Wu Weili. Role of JAK2-STAT3 signaling pathway in tumorigenesis and development[J]. Journal of International Oncology, 2021, 48(12): 739-742.

参考文献 27

[1]	Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994,264(5164):1415-1421. DOI: 10.1126/science.8197455.
[2]	Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact[J]. Nat Rev Mol Cell Biol, 2002,3(9):651-662. DOI: 10.1038/nrm909.
[3]	Liu JF, Deng WW, Chen L, et al. Inhibition of JAK2-STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer[J]. Mol Carcinog, 2018,57(3):429-439. DOI: 10.1002/mc.22767.
[4]	Peng HY, Cheng YC, Hsu YM, et al. MPT0B098, a microtubule inhibitor, suppresses JAK2-STAT3 signaling pathway through modulation of SOCS3 stability in oral squamous cell carcinoma[J]. PLoS One, 2016,11(7):e0158440. DOI: 10.1371/journal.Pone.0158440.
[5]	Yadav A, Kumar B, Datta J, et al. IL-6 promotes head and necktumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway[J]. Mol Cancer Res, 2011,9(12):1658-1667. DOI: 10.1158/1541-7786.MCR-11-0271.
[6]	He HL, Lee YE, Liang PI, et al. Overexpression of JAK2: a predictor of unfavorable prognosis for nasopharyngeal carcinoma[J]. Future Oncol, 2016,12(16):1887-1896. DOI: 10.2217/fon-2016-0025.
[7]	Lin CH, Chiang MC, Chen YJ. STAT3 mediates resistance toanoikis and promotes invasiveness of nasopharyn geal cancer cells[J]. Int J Mol Med, 2017,40(5):1549-1556. DOI: 10.3892/ijmm.2017.3151.
[8]	Xu Y, Jin J, Xu J, et al. JAK2 variations and functions in lung adenocarcinoma[J]. Tumour Biol, 2017,39(6):1010428317711140. DOI: 10.1177/1010428317711140.
[9]	Wang M, Lin T, Wang Y, et al. CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2-STAT3 signaling in human non-small-cell lung cancer cells[J]. Onco Targets Ther, 2017,10:3215-3224. DOI: 10.2147/OTT.S133055.
[10]	Pastuszak-Lewandoska D, Domańska-Senderowska D, Kordiak J, et al. Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non-small-cell lung cancer[J]. Pol Arch Intern Med, 2017,127(11):758-764. DOI: 10.20452/pamw.4115.
[11]	Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p[J]. Life Sci, 2019,239:116984. DOI: 10.1016/j.lfs.2019.116984.
[12]	Fang J, Chu L, Li C, et al. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK-STAT3 pathway[J]. Oncol Rep, 2015,33(1):494-502. DOI: 10.389 2/or.2014.3609.
[13]	Liu JR, Wu WJ, Liu SX, et al. Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2-STAT3 pathway[J]. Pathol Res Pract, 2015,211(6):426-434. DOI: 10.1016/j.prp.2015.01.007.
[14]	Liu J, Mao Y, Zhang D, et al. Retraction notice to "MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma"[J]. Cancer Lett, 2018,422:133. DOI: 10.1016/j.canlet.2018.03.021.
[15]	Yan XL, Luo QY, Zhou SN, et al. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2-STAT3 signaling pathways in gastric cancer[J]. Clin Res Hepatol Gastroenterol, 2020,30:101574. DOI: 10.1016/j.clinre.2020.10.015.
[16]	陶有茂 . MicroRNA-216a通过抑制JAK2-STAT3信号通路抑制胃癌细胞侵袭转移及上皮间质转化[D]. 吉林大学, 2019.
[17]	Xu XF, Gao F, Wang JJ, et al. BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK-STAT3 signaling pathway[J]. Cancer Cell Int, 2019,19:133. DOI: 10.1186/s12935-019-0847-5.
[18]	Hin Tang JJ, Hao Thng DK, Lim JJ, et al. JAK-STAT signaling in hepatocellular carcinoma[J]. Hepat Oncol, 2020, 7(1): HEP18. DOI: 10.2217/hep-2020-0001.
[19]	Kondo R, Ishino K, Wada R, et al. Downregulation of protein disulfide-isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling inhepatocellular carcinoma[J]. Int J Oncol, 2019,54(4):1409-1421. DOI: 10.3892/ijo.2019.4710.
[20]	Choe MH, Min JW, Jeon HB, et al. ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer[J]. Oncotarget, 2015,6(5):2654-2666. DOI: 10.18632/oncotarget.3042.
[21]	Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J]. Gastroenterology, 2014,147(6):1393-1404. DOI: 10.1053/j.gastro.2014.08.039.
[22]	Chang R, Song L, Xu Y, et al. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2-STAT3 axis[J]. Nat Commun, 2018,9(1):3486. DOI: 10.1038/s41467-018-05852-8.
[23]	Cheng M, Liu P, Xu LX. Iron promotes breast cancer cell migration via IL-6/JAK2/STAT3 signaling pathways in a paracrine or autocrine IL-6-rich inflammatory environment[J]. J Inorg Biochem, 2020,210:111159. DOI: 10.1016/j.jinorgbio.2020.11115.
[24]	Wang S, Liang K, Hu Q, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis[J]. J Clin Invest, 2017,127(12):4498-4515. DOI: 10.1172/JCI91553.
[25]	Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases[J]. Pharmacol Res, 2016,111:784-803. DOI: 10.1016/j.phrs.2016.07.038.
[26]	Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib[J]. Cancer Chemother Pharmacol, 2016,77(6):1125-1142. DOI: 10.1007/s00280-016-3012-z.
[27]	Shastri A, Choudhary G, Teixeira M, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells[J]. J Clin Invest, 2018,128(12):5479-5488. DOI: 10.1172/JCI120156.

JAK2-STAT3信号通路在肿瘤发生发展中的作用

Role of JAK2-STAT3 signaling pathway in tumorigenesis and development

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.